Standard BioTools Framtida tillväxt
Future kriterier kontrolleras 0/6
Standard BioTools s intäkter förväntas minska med 5.8% per år medan dess årliga intäkter förväntas växa med 0.9% per år. EPS förväntas falla med 5.3% per år.
Viktig information
-5.8%
Tillväxttakt i vinsten
-5.32%
Tillväxttakt för EPS
| Life Sciences vinsttillväxt | 17.5% |
| Intäkternas tillväxttakt | 0.9% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 06 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Analysuppdatering • Apr 28
LAB: Completed Buyback And 2026 Revenue Outlook Will Support Upside
Analysts have trimmed their price targets on Standard BioTools by $0.00, keeping fair value steady at $1.35 as they factor in a slightly lower discount rate, softer revenue growth assumptions, a marginally reduced profit margin outlook, and a modestly higher future P/E estimate. What's in the News On April 20, 2026, Standard BioTools received a Nasdaq notice that its shares had closed below the $1.00 minimum bid price for 30 consecutive business days, triggering a 180 day compliance period that runs until October 19, 2026 (Nasdaq listing notice).Analysuppdatering • Apr 14
LAB: Completed Buybacks And 2026 Outlook Will Support Future Upside
Analysts have nudged their price target on Standard BioTools slightly higher to $1.35, reflecting minor tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions, while keeping their overall valuation framework broadly unchanged. What's in the News Completion of a share repurchase program, with 13,603,617 shares bought back for a total of $35.91 million under the buyback announced on March 1, 2024 (Key Developments).Analysuppdatering • Mar 31
LAB: Share Buybacks And Steady Outlook Will Support Future Upside
Analysts now see fair value for Standard BioTools holding at $1.35 per share, with a slightly higher discount rate and P/E assumptions, and a less steep projected revenue contraction supporting a steady price target despite mixed tweaks to the model inputs. What's in the News Standard BioTools completed a share repurchase program covering 13,603,617 shares, equal to 7.63% of the company, for a total of $35.91 million under the buyback announced on March 1, 2024 (Key Developments).
Analysuppdatering • Mar 17
LAB: Stable Guidance And Margin Assumptions Will Support Future Earnings Profile
Analysts have maintained their $1.55 price target on Standard BioTools, citing only marginal adjustments to the discount rate, long-term revenue and margin assumptions, along with a slightly higher future P/E expectation. What's in the News Issued earnings guidance for fiscal 2026 with expected revenue in the range of $80 million to $85 million, with seasonality described as similar to prior years (company guidance).Analysuppdatering • Mar 03
LAB: Improved Margin Outlook And Stable Guidance Will Support Future Earnings Profile
Analysts have kept their $1.55 price target for Standard BioTools unchanged, citing slightly higher assumed profit margins and a modestly lower forward P/E, along with an updated view that revenue contraction is now far less severe than previously modeled. What's in the News Issued fiscal 2026 revenue guidance in a range of $80 million to $85 million, with seasonality expected to be similar to prior years (company guidance).
Analysuppdatering • Feb 16
LAB: Imaging Collaboration And 2025 Outlook Will Drive Upside Potential
Analysts have modestly lifted their price target for Standard BioTools to $1.75, pointing to slightly higher assumed profit margins and a marginally richer future P/E multiple, even as they factor in a small additional revenue decline. What's in the News Standard BioTools issued revenue guidance for the fourth quarter of 2025, with expected revenue of approximately $56 million and revenue from continuing operations of about $24 million (company guidance).Analysartikel • Feb 12
Standard BioTools Inc.'s (NASDAQ:LAB) Popularity With Investors Under Threat As Stock Sinks 27%
Standard BioTools Inc. ( NASDAQ:LAB ) shareholders won't be pleased to see that the share price has had a very rough...Analysuppdatering • Feb 02
LAB: Imaging Collaboration And Steady Guidance Will Shape Future Earnings Profile
Analysts have kept their price target for Standard BioTools steady at US$1.55, citing only minor tweaks to inputs such as discount rate, profit margin assumptions and future P/E, which did not meaningfully alter their overall valuation view. What's in the News Standard BioTools issued revenue guidance for the fourth quarter of 2025, with expected revenue of approximately US$56 million and revenue from continuing operations of about US$24 million.Analysartikel • Jan 29
Here's Why We're Not At All Concerned With Standard BioTools' (NASDAQ:LAB) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysuppdatering • Jan 19
LAB: Higher Discount Rate Will Likely Undermine Outlook Despite Guidance
Analysts have trimmed their price target on Standard BioTools from US$1.55 to US$1.35, citing updated assumptions that now reflect a smaller expected revenue decline, a slightly stronger profit margin profile, a lower future P/E estimate, and a higher discount rate. What's in the News Standard BioTools issued revenue guidance for the fourth quarter of 2025, with expected revenue of about US$56 million and revenue from continuing operations of about US$24 million.Analysuppdatering • Jan 05
LAB: Imaging Collaboration And 2025 Outlook Will Support Upside Potential
Analysts have kept their price target for Standard BioTools unchanged at US$1.75, citing only minor tweaks to inputs such as discount rate, revenue contraction assumptions and future P/E, which they view as offsetting each other at this stage. What's in the News Standard BioTools and Molecular Instruments announced a collaboration to develop next-generation Imaging Mass Cytometry workflows that combine HCR Gold for RNA and protein imaging with the Hyperion Imaging System, aiming to support simultaneous analysis of RNA and protein targets in complex tissues (Key Developments).Seeking Alpha • Dec 28
Standard BioTools: Outlook Still Murky
Summary Standard BioTools is trading near cash value post-SomaScan sale, with Casdin Capital raising its stake to 25%. LAB will receive $350M upfront and up to $75M in earnouts from Illumina for SomaScan, leaving $550M in cash post-transaction. Management projects Adj. EBITDA breakeven in 2026 after divestiture and a 20% workforce reduction, but ongoing operations lack clear growth catalysts. An analysis around Standard BioTools follows in the paragraphs below. Read the full article on Seeking AlphaAnalysuppdatering • Dec 18
LAB: Earnings Outlook And Collaboration Will Drive Strong Upside Potential
Analysts have trimmed their price target on Standard BioTools from 2.00 dollars to 1.75 dollars, reflecting slightly higher perceived risk and softer revenue growth expectations, even as projected profit margins and future valuation multiples improve modestly. What's in the News Standard BioTools and Molecular Instruments announced a strategic collaboration to develop next generation Imaging Mass Cytometry workflows that integrate HCR RNA and protein imaging with the Hyperion Imaging System to boost sensitivity and flexibility in spatial biology research (Key Developments).Analysartikel • Dec 05
Subdued Growth No Barrier To Standard BioTools Inc. (NASDAQ:LAB) With Shares Advancing 26%
Standard BioTools Inc. ( NASDAQ:LAB ) shares have had a really impressive month, gaining 26% after a shaky period...Analysuppdatering • Dec 04
LAB: Imaging Collaboration And Steady Outlook Will Support Future Earnings Profile
Analysts have modestly adjusted their price target on Standard BioTools, trimming fair value to approximately 1.55 dollars per share as they factor in a slightly higher discount rate, marginally softer long term profit margin expectations, and a higher projected future earnings multiple. What's in the News Molecular Instruments and Standard BioTools entered a strategic collaboration to develop next generation Imaging Mass Cytometry workflows powered by HCR imaging technologies, including the HCR HiFi Encoder for protein imaging with any primary antibody (Key Developments).Analysuppdatering • Nov 20
LAB: Earnings Outlook Will Benefit From Advanced Imaging Collaboration
Analysts have adjusted their price target for Standard BioTools downward from $1.78 to $1.55. They cited updated expectations around revenue growth and profit margins.Analysuppdatering • Aug 23
SomaLogic Merger And Illumina Partnership Will Unlock New Proteomics Opportunities
The downward revision in Standard BioTools' analyst price target reflects declining net profit margin and a higher future P/E ratio, with the consensus fair value now lowered to $1.78. What's in the News Standard BioTools announced a delay in filing their next 10-Q with the SEC.Analysartikel • Jul 10
Standard BioTools Inc.'s (NASDAQ:LAB) P/S Is Still On The Mark Following 26% Share Price Bounce
The Standard BioTools Inc. ( NASDAQ:LAB ) share price has done very well over the last month, posting an excellent gain...Analysartikel • Jul 05
We're Keeping An Eye On Standard BioTools' (NASDAQ:LAB) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysartikel • May 24
Standard BioTools Inc. (NASDAQ:LAB) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing
The Standard BioTools Inc. ( NASDAQ:LAB ) share price has fared very poorly over the last month, falling by a...
Ny analys • Mar 26
SomaLogic Merger And Illumina Partnership Will Unlock New Proteomics Opportunities
Strategic mergers and partnerships, along with cost synergies, aim to improve profitability and net margins significantly.Analysartikel • Mar 01
Standard BioTools Inc. (NASDAQ:LAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
It's been a mediocre week for Standard BioTools Inc. ( NASDAQ:LAB ) shareholders, with the stock dropping 18% to...Analysartikel • Feb 21
Market Cool On Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 28% Lower
Standard BioTools Inc. ( NASDAQ:LAB ) shareholders won't be pleased to see that the share price has had a very rough...Analysartikel • Feb 09
Is Standard BioTools (NASDAQ:LAB) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Dec 17
After Leaping 35% Standard BioTools Inc. (NASDAQ:LAB) Shares Are Not Flying Under The Radar
Standard BioTools Inc. ( NASDAQ:LAB ) shares have had a really impressive month, gaining 35% after a shaky period...Analysartikel • Oct 26
Standard BioTools (NASDAQ:LAB) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Sep 14
Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher
Those holding Standard BioTools Inc. ( NASDAQ:LAB ) shares would be relieved that the share price has rebounded 33% in...Analysartikel • Aug 05
Newsflash: Standard BioTools Inc. (NASDAQ:LAB) Analysts Have Been Trimming Their Revenue Forecasts
The analysts covering Standard BioTools Inc. ( NASDAQ:LAB ) delivered a dose of negativity to shareholders today, by...Analysartikel • Jul 26
Revenues Tell The Story For Standard BioTools Inc. (NASDAQ:LAB) As Its Stock Soars 42%
Those holding Standard BioTools Inc. ( NASDAQ:LAB ) shares would be relieved that the share price has rebounded 42% in...Analysartikel • Apr 09
Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?
Standard BioTools Inc. ( NASDAQ:LAB ), might not be a large cap stock, but it led the NASDAQGS gainers with a...Analysartikel • Mar 06
Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Standard BioTools fair value estimate is US$3.18 Current share...Analysartikel • Feb 17
Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable
Standard BioTools Inc.'s ( NASDAQ:LAB ) price-to-sales (or "P/S") ratio of 7.1x may look like a poor investment...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 86 | -55 | N/A | N/A | 1 |
| 12/31/2027 | 84 | -54 | -22 | 3 | 3 |
| 12/31/2026 | 82 | -39 | -4 | 72 | 3 |
| 3/31/2026 | 86 | -50 | -94 | -91 | N/A |
| 12/31/2025 | 85 | -59 | -83 | -74 | N/A |
| 9/30/2025 | 86 | -100 | -98 | -87 | N/A |
| 6/30/2025 | 89 | -90 | -105 | -93 | N/A |
| 3/31/2025 | 90 | -98 | -124 | -111 | N/A |
| 12/31/2024 | 91 | -137 | -152 | -143 | N/A |
| 9/30/2024 | 94 | -130 | -149 | -143 | N/A |
| 6/30/2024 | 98 | -129 | -131 | -127 | N/A |
| 3/31/2024 | 103 | -120 | -100 | -97 | N/A |
| 12/31/2023 | 106 | -75 | -46 | -43 | N/A |
| 9/30/2023 | 105 | -76 | -52 | -48 | N/A |
| 6/30/2023 | 105 | -84 | -65 | -62 | N/A |
| 3/31/2023 | 97 | -131 | -86 | -82 | N/A |
| 12/31/2022 | 98 | -190 | -93 | -89 | N/A |
| 9/30/2022 | 109 | -179 | -81 | -77 | N/A |
| 6/30/2022 | 112 | -163 | -66 | -62 | N/A |
| 3/31/2022 | 124 | -117 | -54 | -47 | N/A |
| 12/31/2021 | 131 | -59 | -57 | -44 | N/A |
| 9/30/2021 | 137 | -68 | -64 | -41 | N/A |
| 6/30/2021 | 148 | -60 | -58 | -36 | N/A |
| 3/31/2021 | 143 | -56 | -43 | -24 | N/A |
| 12/31/2020 | 138 | -53 | -28 | -15 | N/A |
| 9/30/2020 | 126 | -48 | -20 | -17 | N/A |
| 6/30/2020 | 113 | -55 | -21 | -17 | N/A |
| 3/31/2020 | 115 | -55 | -23 | -19 | N/A |
| 12/31/2019 | 117 | -65 | N/A | -35 | N/A |
| 9/30/2019 | 117 | -67 | N/A | -30 | N/A |
| 6/30/2019 | 120 | -69 | N/A | -30 | N/A |
| 3/31/2019 | 118 | -71 | N/A | -29 | N/A |
| 12/31/2018 | 113 | -59 | N/A | -25 | N/A |
| 9/30/2018 | 108 | -55 | N/A | -24 | N/A |
| 6/30/2018 | 104 | -56 | N/A | -28 | N/A |
| 3/31/2018 | 102 | -57 | N/A | -32 | N/A |
| 12/31/2017 | 102 | -61 | N/A | -24 | N/A |
| 9/30/2017 | 99 | -68 | N/A | -35 | N/A |
| 6/30/2017 | 97 | -72 | N/A | -41 | N/A |
| 3/31/2017 | 101 | -73 | N/A | -40 | N/A |
| 12/31/2016 | 104 | -76 | N/A | -39 | N/A |
| 9/30/2016 | 110 | -71 | N/A | -33 | N/A |
| 6/30/2016 | 117 | -61 | N/A | -32 | N/A |
| 3/31/2016 | 117 | -57 | N/A | -33 | N/A |
| 12/31/2015 | 115 | -53 | N/A | -35 | N/A |
| 9/30/2015 | 117 | -51 | N/A | -34 | N/A |
| 6/30/2015 | 118 | -56 | N/A | -30 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: LAB förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: LAB förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: LAB förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: LAB s intäkter ( 0.9% per år) förväntas växa långsammare än marknaden för US ( 11.6% per år).
Hög tillväxtintäkter: LAB s intäkter ( 0.9% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om LAB s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/11 18:41 |
| Aktiekurs vid dagens slut | 2026/05/08 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Standard BioTools Inc. bevakas av 13 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Sung Ji Nam | BTIG |
| Bryan Brokmeier | Cantor Fitzgerald & Co. |